{"protocolSection":{"identificationModule":{"nctId":"NCT01365104","orgStudyIdInfo":{"id":"1K23AG030967-01","type":"NIH","link":"https://reporter.nih.gov/quickSearch/1K23AG030967-01"},"secondaryIdInfos":[{"id":"1K23AG030967-01A1","type":"NIH","link":"https://reporter.nih.gov/quickSearch/1K23AG030967-01A1"}],"organization":{"fullName":"Brigham and Women's Hospital","class":"OTHER"},"briefTitle":"Modulation of Cerebral Blood Flow Using Iron Chelators","officialTitle":"Hypoxia-Inducible Transcription Factor 1 (HIF-1)in Vascular Aging","acronym":"DFO"},"statusModule":{"statusVerifiedDate":"2015-01","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2008-03"},"primaryCompletionDateStruct":{"date":"2012-06","type":"ACTUAL"},"completionDateStruct":{"date":"2014-12","type":"ACTUAL"},"studyFirstSubmitDate":"2011-05-31","studyFirstSubmitQcDate":"2011-06-01","studyFirstPostDateStruct":{"date":"2011-06-03","type":"ESTIMATED"},"lastUpdateSubmitDate":"2015-01-26","lastUpdatePostDateStruct":{"date":"2015-01-28","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Farzaneh Sorond","investigatorTitle":"Principle Investigator","investigatorAffiliation":"Brigham and Women's Hospital"},"leadSponsor":{"name":"Brigham and Women's Hospital","class":"OTHER"},"collaborators":[{"name":"National Institute on Aging (NIA)","class":"NIH"}]},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"The purpose of this study is determine if the iron chelator, desferrioxamine can increase blood levels of hypoxia-inducible transcription factor 1 (HIF-1 protein) and to see if there is a corresponding increase in blood flow to the brain."},"conditionsModule":{"conditions":["Stroke","Problem of Aging"],"keywords":["brain blood flow","stroke","cerebrovascular","aging","cerebrovascular hemodynamics"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["EARLY_PHASE1"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"CROSSOVER","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"TRIPLE","whoMasked":["PARTICIPANT","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":97,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Healthy young","type":"EXPERIMENTAL","description":"Each subject comes for 2 visits. There is a randomized, double-blind, crossover design so each subject will receive active drug during one visit and placebo during the other.","interventionNames":["Drug: desferrioxamine"]},{"label":"healthy old","type":"EXPERIMENTAL","description":"Each subject comes for 2 visits. There is a randomized, double-blind, crossover design so each subject will receive active drug during one visit and placebo during the other.","interventionNames":["Drug: desferrioxamine"]}],"interventions":[{"type":"DRUG","name":"desferrioxamine","description":"intravenous infusion at 10mg/kg/hr for a total of 6 hours at final infused doses of 60mg/kg.","armGroupLabels":["Healthy young","healthy old"],"otherNames":["Desferal, desferoxamine"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Define change from baseline cerebral blood flow after receiving DFO infusion.","description":"Cerebral blood flow is measured with transcranial Doppler ultrasound at baseline and then study drug is initiated. Blood flow is measured again after 3 hours of infusion, 6 hours of infusion, then once more 3 hours after the infusion is complete.","timeFrame":"baseline, 3hr, 6hr, 9hr"},{"measure":"Determine if DFO changes blood HIF-1 levels from baseline and whether this correlates with changes in cerebrovascular hemodynamics.","description":"Blood samples are taken at each time point and will be correlated with ultrasound blood flow measures taken at baseline, 3hrs of infusion, 6hrs of infusion, and 3 hours after infusion is complete.","timeFrame":"baseline, 3hr, 6hr, 9hr"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* healthy adults between the ages of 18-80 years.\n\nExclusion Criteria:\n\n* subjects taking vasoactive medications,\n* hypertension,\n* pregnant women, smokers,\n* COPD,\n* asthma,\n* diabetes mellitus,\n* intracranial or carotid stenosis,\n* hepatic disease,\n* renal disease,\n* bone marrow suppression,\n* cardiac disease,\n* heart failure,\n* iron deficiency,\n* history of cancer,\n* history of head trauma,\n* subarachnoid hemorrhage,\n* central nervous system vasculitis,\n* multiple sclerosis,\n* migraines,\n* seizures,\n* sickle cell disease or trait,\n* cardiac arrhythmia,\n* unable to give informed consent, or\n* poor transcranial Doppler insonation windows.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Farzaneh Sorond, MD, PhD","affiliation":"Brigham and Women's Hospital","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Brigham and Women's Hospital","city":"Boston","state":"Massachusetts","zip":"02115","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}}]},"referencesModule":{"references":[{"pmid":"26304864","type":"DERIVED","citation":"Sorond FA, Tan CO, LaRose S, Monk AD, Fichorova R, Ryan S, Lipsitz LA. Deferoxamine, Cerebrovascular Hemodynamics, and Vascular Aging: Potential Role for Hypoxia-Inducible Transcription Factor-1-Regulated Pathways. Stroke. 2015 Sep;46(9):2576-83. doi: 10.1161/STROKEAHA.115.009906. Epub 2015 Jul 30."}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M3875","name":"Hypoxia","relevance":"LOW"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"meshes":[{"id":"D000003676","term":"Deferoxamine"}],"ancestors":[{"id":"D000017262","term":"Siderophores"},{"id":"D000007502","term":"Iron Chelating Agents"},{"id":"D000002614","term":"Chelating Agents"},{"id":"D000064449","term":"Sequestering Agents"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"}],"browseLeaves":[{"id":"M10223","name":"Iron","relevance":"LOW"},{"id":"M6568","name":"Deferoxamine","asFound":"Vesatolimod","relevance":"HIGH"},{"id":"M5550","name":"Chelating Agents","relevance":"LOW"},{"id":"M10224","name":"Iron Chelating Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"Micro","name":"Micronutrients"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}